Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

Abstract Based on clinical activity in phase 2 studies, lenalidomide was evaluated in a phase 2/3 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Following tumor lysis syndrome (TLS) complications, the protocol was amended to a phase 1 study to identify the maximum tolerated dose-escalation level (MTDEL). Fifty-two heavily pretreated patients, 69% with bulky disease and 48% with high-risk genomic abnormalities, initiated lenalidomide at 2.5 mg/day, with dose escalation until the MTDEL or the maximum assigned dose was attained. Lenalidomide was safely titrated to 20 mg/day; the MTDEL was not reached. Most common grade 3–4 adverse events were neutropenia and thrombocytopenia; TLS was mild and rare. The low starting dose and conservative dose escalation strategy resulted in six partial responders and 30 patients obtaining stable disease. In summary, lenalidomide 2.5 mg/day is a safe starting dose that can be titrated up to 20 mg/day in patients with CLL.

[1]  M. Czuczman,et al.  Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response , 2012, Cancer.

[2]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[3]  M. Hallek,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Briones,et al.  Emerging therapies for patients with advanced chronic lymphocytic leukaemia. , 2009, Blood reviews.

[5]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[6]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[7]  Z. Estrov,et al.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.

[8]  Claire Dearden,et al.  Disease-specific complications of chronic lymphocytic leukemia. , 2008, Hematology. American Society of Hematology. Education Program.

[9]  J. Zeldis,et al.  Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[11]  H. Kantarjian,et al.  The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy , 2007, Leukemia & lymphoma.

[12]  M. Czuczman,et al.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[14]  M. Cairo,et al.  Tumour lysis syndrome: new therapeutic strategies and classification , 2004, British journal of haematology.

[15]  H. Kantarjian,et al.  Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.

[16]  R. Figlin,et al.  Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High‐grade non‐Hodgkin's lymphoma and chronic lymphocytic leukemia , 1999, American journal of hematology.

[17]  B. Cheson,et al.  Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Diehl,et al.  Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) , 1998, Annals of Hematology.

[19]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.